更正：意外的发作：骨发作作为肺癌患者对酪氨酸激酶抑制剂治疗的反应
Correction: A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient.
作者信息
De Bondt Charlotte, Snoeckx Annemiek, Raskin Jo
机构信息
Antwerp University Hospital and University of Antwerp, BE.
出版信息
J Belg Soc Radiol. 2020 Jun 8;104(1):28. doi: 10.5334/jbsr.2163.
Abstract
[This corrects the article DOI: 10.5334/jbsr.1907.].
摘要
[本文更正文章DOI：10.5334/jbsr.1907。]
相似文献
1
Correction: A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient.更正：意外的发作：骨发作作为肺癌患者对酪氨酸激酶抑制剂治疗的反应
J Belg Soc Radiol. 2020 Jun 8;104(1):28. doi: 10.5334/jbsr.2163.
2
A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression.意想不到的“ flare ”：一名肺癌患者中骨“ flare ”作为对酪氨酸激酶抑制剂治疗的反应：肺癌患者出现新的成骨性骨病变可能代表骨“ flare ”，不应误诊为疾病进展。
J Belg Soc Radiol. 2020 Apr 27;104(1):18. doi: 10.5334/jbsr.1907.
3
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.厄洛替尼治疗期间发生成骨骨病变提示非小细胞肺癌患者的主要缓解：简要报告。
J Thorac Oncol. 2010 Apr;5(4):554-7. doi: 10.1097/JTO.0b013e3181d3e47e.
4
Alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: Report of a case and case review.表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌后碱性磷酸酶耀斑现象：一例报告及病例回顾
Respir Med Case Rep. 2014 Oct 23;13:51-3. doi: 10.1016/j.rmcr.2014.09.003. eCollection 2014.
5
Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.表皮生长因子受体酪氨酸激酶抑制剂治疗突变型非小细胞肺癌期间的成骨细胞进展：一个潜在的失误。
Tumori. 2017 Jan 21;103(1):66-71. doi: 10.5301/tj.5000423. Epub 2015 Sep 19.
6
Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy.在接受贝伐单抗联合标准化疗的非小细胞肺癌（NSCLC）患者中，F18氟代脱氧葡萄糖正电子发射断层显像（F18-FDG PET）上出现成骨性骨闪烁现象。
J Thorac Oncol. 2009 Mar;4(3):429-31. doi: 10.1097/JTO.0b013e3181989e12.
7
8
Metabolic flare phenomenon on 18 fluoride-fluorodeoxy glucose positron emission tomography-computed tomography scans in a patient with bilateral breast cancer treated with second-line chemotherapy and bevacizumab.一名接受二线化疗和贝伐单抗治疗的双侧乳腺癌患者在18氟-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描中的代谢耀斑现象
Indian J Nucl Med. 2015 Apr-Jun;30(2):145-7. doi: 10.4103/0972-3919.152978.
9
Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib.吉非替尼治疗的非小细胞肺癌患者中的骨扫描闪烁现象。
Clin Nucl Med. 2009 Jun;34(6):346-9. doi: 10.1097/RLU.0b013e3181a344df.
10
Disease flare after gefitinib discontinuation.吉非替尼停药后疾病复发。
Respir Investig. 2015 Mar;53(2):68-72. doi: 10.1016/j.resinv.2014.10.005. Epub 2014 Nov 13.
引用本文的文献
1
Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report.晚期一线内分泌治疗后发生骨转移的转移性乳腺癌假性进展：一例报告
Front Oncol. 2023 Jan 4;12:1099164. doi: 10.3389/fonc.2022.1099164. eCollection 2022.
2
Is hyperprogressive disease a specific phenomenom of immunotherapy?超进展性疾病是免疫治疗的一种特定现象吗？
Explor Target Antitumor Ther. 2020;1(6):427-433. doi: 10.37349/etat.2020.00027. Epub 2020 Dec 28.
本文引用的文献
1
A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression.意想不到的“ flare ”：一名肺癌患者中骨“ flare ”作为对酪氨酸激酶抑制剂治疗的反应：肺癌患者出现新的成骨性骨病变可能代表骨“ flare ”，不应误诊为疾病进展。
J Belg Soc Radiol. 2020 Apr 27;104(1):18. doi: 10.5334/jbsr.1907.
Zotero 插件